Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
Helping biologists identify target and off-target proteins through pull-down experiments by providing customized photo linkers, biotin-conjugated linkers, and more.
Assisting customers in designing linkers, molecules, and conjugated products to identify protein-protein interactions effectively.
Expertise in the field of small molecules, from design to discovery to development, ready to assist in realizing your research and development goals.
The core of Ruhvenile is dedicated to the research of natural remedies and the isolation of the active principles that are responsible for health benefits.
Our company sets out to create new formulations using natural remedies as well as helping the research on phytopharmaceuticals providing high-quality purified compounds of natural origin for the study of their beneficial properties
Ruhvenile is keen to tackle the need of distributing cheaper, easily available, and easy-to-implement diagnostic kits to avail the fast diagnosis of diseases with a higher incidence in the Indian subcontinent.
With several contacts with European and American manufacturers, our team distributes kits for the diagnosis of tuberculosis, malaria, and forms of cancer that show a higher incidence rate among the Indian population.
Ruhvenile offers drug development services and drug design in silico, including molecular docking, drug target identification, drug discovery screening – small molecule screening, library screening, ion channel screening – fragment-based drug design,
ligand-based drug design, ligand-protein binding, protein-ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification, and lead optimization.
Anticancer drug discovery projects are being pursued by many biotech companies in India and the US. Over half of these are devoted to the development of cancer drugs and to the treatment of cancer. Ruhvenile offers drug-like lead compounds, and chemical compound libraries including screening compounds: small molecules, natural compounds, diversity libraries, and custom libraries, such as angiogenesis inhibitors, GPCR libraries, kinase libraries, and kinase inhibitor libraries.
Our drug design consultancy helps scientists to develop anticancer drugs, work on tumor regression, and identify new drug targets and drug candidates.
At Ruhvenile, you can purchase custom peptides of the highest quality at the best possible price. With advanced peptide methodologies, we produce peptides from milligrams to several hundred grams using solid-phase and/or liquid-phase approaches.
The delivery time for custom peptide synthesis may vary depending on the peptide’s length and complexity. State-of-the-art peptide synthesizers and HPLC and mass spectrometry equipment are used for the synthesis, purification, and characterization of our products. All of which include HPLC and mass spectroscopy data. Confidentiality of all orders is assured.
Ruhvenile provides several hundred different small molecules and reagents for all your need of chemical synthesis, and purification for research purposes.
Our company provides small molecules for all your needs!
After initial biological testing of selected compounds, the verified hits often undergo hit-to-lead analysis in order to progress several sets of compounds into just a few preclinical candidates.
We design lead series for the target on the basis of verified hits, provided by a close collaboration between our partners and chemistry teams, in two steps:
1. Creating new targeted libraries on the basis of hits verified in the initial biological testing stage.
2. Carrying out in silico screening of these compounds against the target.
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling technique to predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of a compound in the body and is used in pharmaceutical research.
ADME describes the ability of a potential new drug compound to perform a pharmacological activity.
Our computer calculations will help you to estimate preclinical or non-clinical ADME parameters including:
Our protocols have been developed to provide quantitative information for early assessment of compound toxicity and include:
1. MRTD – maximum recommended therapeutic dose, MRDD – maximum recommended daily allowance, LD50.
2. To characterize the toxicity of a drug lead we screen the compound against a panel of more than 200 human proteins to characterize the toxicity of the compound.
This service predicts drug toxicity and LD50. First, a toxicological profile is predicted by in silico screening of a drug candidate molecule against hundreds of diverse proteins representing different active site types of the human proteome. The active site types that show high affinity for a compound (IC50) are considered sensitive. In the second round of the toxicity assessment procedure, all proteins similar to those with sensitive active site types are included in the screening. As a result, we obtain IC50 (IC50, represents the concentration of an inhibitor that is required for 50% inhibition of its target) of a tested compound for every protein from our toxicological protein platform. On the basis of this information, we draw a conclusion about the adverse reaction targets of a compound and its possible adverse effects.
Ruhvenile offers pull-down assays and experiments at competitive prices
Ruhvenile provides services on Nuclear Magnetic Resonance (NMR) for small molecules, and proteins and determines the structure of the same for your individual and/or institutional progress.
Do you need NMR service, or structure elucidation for your small organic molecules, Natural products, proteins, and Biologics? then Ruhvenile is the right place to get service through its highly experienced team.
All the NMR experiments are done on 500 MHz with CryoProbe.
